Table 1.
Neutralizing monoclonal antibodies for SARS-CoV-2 currently in development up to 11 December 2020
| Sponsors | Drug code/International proprietary name | Status | Trial ID | Actual starta | Estimated primary completiona |
|---|---|---|---|---|---|
| Junshi Biosciences and Eli Lilly and Company | JS016, etesevimab | EUA when used in combination with bamlanivimabb |
5 Jun. 2020 19 Jun. 2020 17 Jun. 2020 |
11 Dec. 2020 2 Oct. 2020c 20 Sep. 2020c |
|
| Tychan Pte Ltd | TY027 | Phase I; phase III pending |
9 Jun. 2020 4 Dec. 2020d |
19 Nov. 2020c 31 Aug. 2021 |
|
| Brii Biosciences | BRII-196 | Phase I | NCT04479631 | 12 Jul. 2020 | Mar. 2021 |
| Brii Biosciences | BRII-198 | Phase I | NCT04479644 | 13 Jul. 2020 | Mar. 2021 |
| AbbVie | ABBV-47D11 | Phase I pending | NCT04644120 | 10 Dec. 2020 | 5 Sep. 2021 |
| Sorrento Therapeutics Inc. | COVI-GUARD (STI-1499) | Phase I | NCT04454398 | Sep. 2020d | Jan. 2021 |
| Mabwell (Shanghai) Bioscience Co. Ltd | MW33 | Phase I | NCT04533048 | 7 Aug. 2020 | 16 Nov. 2020c |
| HiFiBiO Therapeutics | HFB30132A | Phase I | NCT04590430 | 20 Oct. 2020 | Apr. 2021 |
| Ology Bioservices | ADM03820 | Phase I pending | NCT04592549 | 4 Dec. 2020 | 30 Sep. 2021 |
| Hengenix Biotech Inc | HLX70 | Phase I pending | NCT04561076 | 9 Dec. 2020d | 6 Sep. 2021 |
| University of Cologne and Boehringer Ingelheim | DZIF-10c | Phase I/II pending |
14 Dec. 2020 8 Dec. 2020 |
31 Jul. 2021 31 Jul. 2021 |
|
| Sorrento Therapeutics Inc. | COVI-AMG (STI-2020) | Phase I/II pending | NCT04584697 | Dec. 2020c | Apr. 2021 |
| Beigene | BGB DXP593 | Phase I; phase II pending |
NCT04532294 (phase I) NCT04551898 (phase II pending) |
8 Sep. 2020 2 Dec. 2020 |
19 Feb. 2021 25 Jan. 2021c |
| Sinocelltech Ltd | SCTA01 | Phase I; phase II/III pending |
24 Jul. 2020 10 Feb. 2021d |
17 Nov. 2020c 10 May 2021 |
|
| AstraZeneca | AZD7442 (AZD8895 and AZD1061) | Phase I; phase III pending |
18 Aug. 2020 21 Nov. 2020 2 Dec. 2020 |
25 Oct. 2021 21 Apr. 2021 21 Jan. 2022 |
|
| Celltrion | CT-P59 | Phase I; phase II/III |
18 Jul. 2020 4 Sep. 2020 25 Sep. 2020 |
31 Aug. 2020 22 Oct. 2020 Dec. 2020 |
|
| Vir Biotechnology Inc and GlaxoSmithKline | VIR-7831/GSK4182136 | Phase II/III | NCT04545060 | 27 Aug. 2020 | Mar. 2021 |
| AbCellera and Eli Lilly and Company | Bamlanivimab; combination of bamlanivimab and etesevimab | EUAb |
NCT04411628 (phase I) NCT04427501 (phase II) NCT04497987 (phase III) NCT04501978 (phase III) NCT04518410 (phase II/III) |
28 May 2020 17 Jun. 2020 2 Aug. 2020 4 Aug. 2020 19 Aug. 2020 |
26 Aug. 2020c 20 Sep. 2020c 8 Mar. 2021 Jul. 2022 May 2023 |
| Regeneron | REGN-COV2 (casirivimab and imdevimab) | EUAb |
NCT04425629 (phase I/II) NCT04426695 (phase I/II) NCT04452318 (phase III) |
16 Jun. 2020 11 Jun. 2020 13 Jul. 2020 |
10 Apr. 2021 16 Apr. 2021 15 Jun. 2021 |
A complete list can be found at COVID-19 Biologics Tracker. EUA, emergency use authorization; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. aDates as of 7 April 2021. bHave recieved EUA in the United States. cActual primary completion date. dEstimated start date.